logo
BP share buyback outlook at risk from oil price slump, analysts say

BP share buyback outlook at risk from oil price slump, analysts say

Reuters23-04-2025
LONDON, April 23 (Reuters) - BP (BP.L), opens new tab may be forced to cut or even scrap its share buyback programmes over the next year unless oil prices recover, analysts say, adding that would increase pressure on its already underperforming shares.
Oil majors and other resource companies have made increased use of share buybacks and dividends to reward shareholders in recent years.
The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.
Three analysts said the risk for BP was that weaker oil prices would mean it could not sustain its buyback programme, aggravating the problem of BP's underperformance versus peers.
A February strategy revamp was designed to overcome investor doubts. The revamp, however, included BP shrinking guidance for its first-quarter buyback to $0.75-$1.0 billion, implying a $3-$4 billion annual buyback, as it tries to cut debt.
This compares with a $3.5 billion buyback programme for the first quarter alone at Shell, which has said it will continue buybacks even if oil prices fall to $50 a barrel.
Currently international Brent crude is trading above $65 , but is under pressure from increased output from the OPEC+ producer group and the economic risks of U.S. tariffs.
UBS analyst Joshua Stone said he expected BP's quarterly buybacks to fall to a quarterly $500 million after the first quarter.
He said the market was pricing BP shares on the basis of a buyback programme of around $3 billion a year.
It means BP's stock could fall by 15% if it cut the buyback to $2 billion a year and by 30% if the buyback was scrapped, said Stone.
RBC analysts, meanwhile, expect BP to suspend all buybacks next year if oil falls to $60 a barrel.
"Given its higher leverage position than peers, we've had more questions on what price BP can sustain its current buyback at than any other company," RBC analyst Biraj Borkhataria wrote in a note this month.
Bank of America expects BP will cut buybacks to $2.5 billion this year if oil prices trade at $65 a barrel. At $60 a barrel, BofA also anticipates BP would suspend its buybacks.
At its February strategy update, BP said it assumed Brent prices would average $71.5-$74.4 a barrel between 2025-2027, while benchmark Henry hub gas prices would be $4.1-$4.3 per million British thermal units through 2027 compared to the current prices of around $3 .
Asked about buybacks, a BP spokesperson referred to the February strategy update, when BP said it aimed to distribute 30-40% of operating cash flow via dividends, which it plans to raise by 4% a year, and buybacks.
BP has said that, in addition to its disposal programme, it is cutting its costs by $4-$5 billion a year, expects its refining business to improve and has projects starting up that will help its cash flow.
BP is due to report first-quarter results on April 29.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Argentina oil and gas exports rise 36% in first half of year, business group says
Argentina oil and gas exports rise 36% in first half of year, business group says

Reuters

time15 minutes ago

  • Reuters

Argentina oil and gas exports rise 36% in first half of year, business group says

BUENOS AIRES, July 31 (Reuters) - Argentina's oil and gas exports rose 36% to $3.7 billion in the first half of the year, compared to the same period last year, Argentina's Chamber of Hydrocarbons Exploration and Production said in a statement on Thursday. The group added it expected exports to bring in more than $6 billion this year, and surpass a goal of $25 billion by the end of the decade.

Daimler Truck slashes key profit forecast on North America weakness
Daimler Truck slashes key profit forecast on North America weakness

Reuters

time15 minutes ago

  • Reuters

Daimler Truck slashes key profit forecast on North America weakness

FRANKFURT, July 31 (Reuters) - Daimler Truck ( opens new tab on Thursday slashed a key profit forecast for 2025 due to "continuous market weakness in North America". The German company now expects adjusted earnings before interest and taxes (EBIT) in a range of 3.6 billion euros to 4.1 billion euros ($4.1 billion to $4.7 billion), compared with 4.7 billion euros reported for 2024. That would mark a drop of as much as 23%. The company previously forecast that adjusted EBIT for 2025 would be just 5% lower, and could even rise 5%. ($1 = 0.8755 euros)

Bristol Myers tops revenue expectations on strength of older drugs, shares fall
Bristol Myers tops revenue expectations on strength of older drugs, shares fall

Reuters

time17 minutes ago

  • Reuters

Bristol Myers tops revenue expectations on strength of older drugs, shares fall

July 31 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling brands, but failed to convince investors that newer products could drive future growth and shares fell nearly 5%. Revenue in the quarter, which analysts had expected to fall due to the loss of patent protection on some of its products, including blood cancer therapy Revlimid, rose 1% to $12.3 billion. Analysts, on average, were looking for revenue of $11.4 billion, according to LSEG data. The quarterly sales beat was driven by legacy products such as the blood thinner Eliquis, which is expected to face competition from cheaper generics next year, and demand for Revlimid, which has held up better than expected, said Raymond James analyst Sean McCutcheon. However, "investors don't see the beat as an indicator of future growth prospects," McCutcheon said. Sales of Eliquis, which Bristol Myers shares with Pfizer (PFE.N), opens new tab, rose 8% to $3.7 billion in the quarter, while cancer immunotherapy Opdivo brought in $2.6 billion, up 7% from a year ago. Analysts, on average, had forecast sales of $3.3 billion and $2.3 billion, respectively. Revlimid sales fell 38% to $838 million, but still topped analyst estimates by about $300 million. The U.S. drugmaker said it earned $2.9 billion, or $1.46 per share, down from $4.2 billion, or $2.07, a year earlier. Analysts had expected earnings of $1.07 a share. Bristol has been contending with a steep revenue decline from Revlimid, which raked in nearly $13 billion in 2021 but $5.8 billion last year due to generic competition. Some of its other cancer drugs such as Pomalyst, Sprycel and Abraxane are contending with the same issue. Still, Revlimid has performed better than initially feared, and the company now expects 2025 sales of around $3 billion, Chief Commercialization Officer Adam Lenkowsky said. The company had previously said it expected 2025 Revlimid sales to be closer to $2.5 billion. Investors are closely watching Bristol's newer products, including cell therapy Breyanzi and schizophrenia treatment Cobenfy, to gauge whether they can drive the next phase of growth as sales of older blockbuster treatments decline. McCutcheon said company comments suggest data from a trial testing Cobenfy for Alzheimer's disease may come a bit later than previously anticipated - by the end of this year rather than early fourth quarter. The company said it was conducting reviews of trial sites, which could delay reporting of results, but Bristol is still targeting by the end of this year. Bristol Myers raised its full-year revenue forecast to $46.5 billion to $47.5 billion from its prior view of $45.8 billion to $46.8 billion. Last month, Bristol agreed to pay up to $11.1 billion in a partnership deal with Germany's BioNTech ( opens new tab to develop next-generation cancer treatments that could take on rival Merck's (MRK.N), opens new tab best-selling immunotherapy Keytruda. Bristol recorded a charge of 57 cents per share in the second quarter related to the deal. Including the charge, it now expects full-year earnings to be $6.35 to $6.65 a share. Analysts are estimating 2025 earnings of around $6.24. Bristol's 2025 operating expenses forecast of $16.5 billion, up from its previous view of $16.2 billion, could be contributing to the share price decline, Piper Sandler analysts said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store